Table 3.
Pooled Analysis and Meta-Analysis for the RR
| Parameter | Pooled Analysis (n = 638) |
Meta-Analysis (random effect; n = 638) |
||||||
|---|---|---|---|---|---|---|---|---|
| Univariable |
Multivariable |
Univariable |
Multivariable |
|||||
| median RR (%; 95% CI) | P* | t | P† | Median RR (%; 95% CI) | P‡ | z | P§ | |
| Total studies | 8 (6.8 to 8.9) | 12.7 (11.6 to 13.9) | ||||||
| Personalized strategy | < .001 | 13.4 | < .001 | < .001 | 13.0 | < .001 | ||
| Yes | 29.2 (24 to 35) | 31 (26.8 to 35.6) | ||||||
| No | 6.2 (5 to 7.4) | 10.5 (9.6 to 1.5) | ||||||
| Chemotherapy status | < .001 | 6.1 | < .001 | < .001 | 4.6 | < .001 | ||
| Chemotherapy naïve | 14 (10 to 23) | 20 (16.6 to 24.1) | ||||||
| Prior chemotherapy | 6.6 (5 to 8) | 11.3 (10.2 to 12.5) | ||||||
| Tumor type | < .001 | 14.0 | < .001 | < .001 | 10.7 | < .001 | ||
| Solid | 6.2 (5 to 7) | 10.6 (9.6 to 11.6) | ||||||
| Hematologic | 27.6 (21.5 to 33) | 31.0 (26.8 to 35.4) | ||||||
| Agent class | < .001 | 4.6 | < .001 | < .001 | 7.5 | < .001 | ||
| Cytotoxic | 11.9 (9.3 to 14.5) | 16.1 (14.3 to 18) | ||||||
| Targeted | 5.8 (5 to 7.1) | 11.2 (9.9 to 12.7) | ||||||
| FDA/EMA approval | < .001 | 3.8 | < .001 | < .001 | 3.7 | < .001 | ||
| No | 3 (1.3 to 5) | 7.1 (5.6 to 8.9) | ||||||
| Yes | 9 (8 to 11) | 14.4 (13.1 to 15.9) | ||||||
| 5-Year impact factor‖ | < .001 | 2.3 | .021 | < .001 | 2.7 | .006 | ||
| ≤ 10 | 7 (5.8 to 8.2) | 12.2 (11.1 to 13.5) | ||||||
| > 10 | 13.8 (9.6 to 21) | 16 (12.8 to 19.9) | ||||||
| Study design | .523 | — | — | .032 | 1.9 | .058 | ||
| Randomized | 7 (5 to 8.9) | 10.2 (8.2 to 12.7) | ||||||
| Nonrandomized | 8 (6.6 to 9) | 13.2 (12 to 14.6) | ||||||
| No. of patients per arm¶ | < .001 | 1.0 | .308 | .258 | — | — | ||
| ≤ 35 | 4.6 (3.3 to 8) | 12.3 (10.8 to 13.9) | ||||||
| > 35 | 9 (8 to 11.6) | 13.6 (12 to 15.3) | ||||||
| Administration route | .041 | 0.8 | .406 | .159 | — | — | ||
| Oral | 8.9 (6.7 to 10) | 13.6 (12 to 15.3) | ||||||
| Injection | 7 (5.2 to 8.2) | 12.0 (10.5 to 13.6) | ||||||
| No. of treating centers | .356 | — | — | .017 | 2.3 | .024 | ||
| Single center | 9.8 (5.7 to 16) | 16.1 (13.4 to 19.2) | ||||||
| Multiple centers | 7.4 (6 to 8.6) | 11.9 (10.7 to 13.2) | ||||||
NOTE. Only variables that were significant in the univariable models were included in the multivariable analysis. The t and z values are used to compute the corresponding P values, and the higher they are, the more they contribute to the model. The pooled analysis and meta-analysis both included 638 arms.
Abbreviations: EMA, European Medicines Agency; FDA, US Food and Drug Administration; RR, response rate.
Wilcoxon test; the median in the univariable was not weighted.
Multiple linear regression model using a weighted least squares model.
Mixed effects analysis.
Random effects meta-regression model.
Cutoff value chosen to discriminate higher impact factor journals versus lower impact factor journals (sum of median and interquartile range).
Cutoff value used was the median of distribution.